These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 7906300)

  • 1. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160.
    Wahren B; Bratt G; Persson C; Levén B; Hinkula J; Gilljam G; Nordlund S; Eriksson L; Volvovitz F; Broliden PA
    J Acquir Immune Defic Syndr (1988); 1994 Mar; 7(3):220-9. PubMed ID: 7906300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
    Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
    AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.
    Levi M; Rudén U; Birx D; Loomis L; Redfield R; Lövgren K; Akerblom L; Sandström E; Wahren B
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.
    Redfield RR; Birx DL; Ketter N; Tramont E; Polonis V; Davis C; Brundage JF; Smith G; Johnson S; Fowler A
    N Engl J Med; 1991 Jun; 324(24):1677-84. PubMed ID: 1674589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.
    Orentas RJ; Hildreth JE; Obah E; Polydefkis M; Smith GE; Clements ML; Siliciano RF
    Science; 1990 Jun; 248(4960):1234-7. PubMed ID: 2190315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Belshe RB; Newman FK; Frey SE
    Vaccine; 1992; 10(6):383-8. PubMed ID: 1534641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection.
    Clerici M; Tacket CO; Via CS; Lucey DR; Muluk SC; Zajac RA; Boswell RN; Berzofsky JA; Shearer GM
    Eur J Immunol; 1991 Jun; 21(6):1345-9. PubMed ID: 1845391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
    Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
    J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
    Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and characterization of human immunodeficiency virus type 1 (HIV-1) envelope-specific CD4+ T lymphocyte lines from HIV-1-seropositive patients.
    Ratto S; Sitz KV; Scherer AM; Manca F; Loomis LD; Cox JH; Redfield RR; Birx DL
    J Infect Dis; 1995 Jun; 171(6):1420-30. PubMed ID: 7769275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A; Gluckman JC; Rochat H; Montagnier L; Bahraoui E
    J Virol; 1992 Apr; 66(4):2473-83. PubMed ID: 1347797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoproliferative responses to mitogens and HIV-1 envelope glycoprotein among volunteers vaccinated with recombinant gp160.
    Tacket CO; Baqar S; Munoz C; Murphy JR
    AIDS Res Hum Retroviruses; 1990 Apr; 6(4):535-42. PubMed ID: 2187503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific western blot bands are associated with initial CD4+ lymphocyte counts in human immunodeficiency virus seroconverters. The Navy HIV Working Group.
    Garland FC; Garland CF; Gorham ED; Brodine SK; Weiss PJ
    Ann Epidemiol; 1994 Jan; 4(1):27-31. PubMed ID: 7911377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
    Keefer MC; Graham BS; Belshe RB; Schwartz D; Corey L; Bolognesi DP; Stablein DM; Montefiori DC; McElrath MJ; Clements ML
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of mice with human immunodeficiency virus glycoprotein gp160 peptide 315-329 induces both class I- and class II-restricted T cells: not all T cells can respond to whole molecule stimulation.
    Moore RL; Fox BS
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):51-9. PubMed ID: 7678972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines.
    el-Daher N; Keefer MC; Reichman RC; Dolin R; Roberts NJ
    J Infect Dis; 1993 Aug; 168(2):306-13. PubMed ID: 8335968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop.
    Ratto S; Sitz KV; Scherer AM; Loomis LD; Cox JH; Redfield RR; Birx DL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):128-36. PubMed ID: 8556394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.